Declines in Revenue and Profit Due to Drug Price Revisions, Lower License Income and Other Factors
First written in FY2017. 10 of 34 entries say "Worsened", first in FY2018. Latest entry: FY2026.
KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2020.
1 other company's latest entry also says "Other".
- FY2026Lower revenue, operating profit, ordinary profit and net incomeAnnual report
「Net sales were ¥126,257 million, down 2.9% year on year; operating profit was ¥3,567 million, down 71.6%; ordinary profit was ¥4,031 million, down 69.5%; and net income attributable to owners of the parent was ¥3,448 million, down 62.0%.」
For the full fiscal year, sales, operating profit, ordinary profit, and net income declined due to the absence of the upfront payment for KRP-M223 and higher research and development expenses arising from upfront payments and other costs for in-licensed products. - FY2026-H1Higher sales, lower operating profit, lower ordinary profit, and higher net incomeAnnual report
「Net sales increased to ¥58,731 million, up ¥3,592 million, or 6.5%, from the same period of the previous year. Operating profit was ¥1,363 million, down 12.0% year on year, and ordinary profit was ¥1,582 million, down 22.8%. Interim net income attributable to owners of the parent was ¥1,494 million, up 19.0% year on year.」
Sales increased during the interim period, while operating profit and ordinary profit declined due in part to higher costs associated with acquiring in-licensed products. Interim net income increased due to extraordinary income. - FY2025Revenue, operating and ordinary income growth, with higher net incomeAnnual report
「Net sales ¥130,087 million (up 8.8% year on year); Operating profit ¥12,567 million (up 101.6% year on year); Ordinary profit ¥13,219 million (up 93.8% year on year); Net income attributable to owners of the parent ¥9,086 million (up 66.0% year on year)」
Higher sales of new drugs, upfront payments under out-licensing agreements, and increased sales of generic drugs resulted in net sales, operating profit, ordinary profit, and net income attributable to owners of the parent all exceeding the previous fiscal year. - FY2025-H1Higher sales, higher operating profit, higher ordinary profit, lower net incomeAnnual report
「Net sales increased to ¥55,139 million, up ¥202 million, or 0.4%, year on year. Operating profit increased to ¥1,549 million, up ¥213 million, or 16.0%, year on year. Ordinary profit was ¥2,050 million, up 29.9% year on year, due in part to foreign exchange gains. Meanwhile, interim net income attributable to owners of the parent was ¥1,255 million, down 33.6% year on year.」
For the six-month consolidated accounting period, sales, operating profit, and ordinary profit increased, while interim net income attributable to owners of the parent declined due in part to the absence of gains on the sale of investment securities. - FY2024Higher sales, higher operating profit, higher net incomeAnnual report
「Net sales ¥119,532 million (up 5.5% year on year); Operating profit ¥6,013 million (up 17.4% year on year); Ordinary profit ¥6,602 million (up 13.3% year on year); Net income attributable to owners of the parent ¥5,322 million (up 12.7% year on year)」
For the fiscal year ended March 2024, net sales, operating profit, ordinary profit, and net income attributable to owners of the parent all exceeded the previous fiscal year. - FY2024-Q3Higher net sales, lower operating income, lower net incomeAnnual report
「Total net sales increased to ¥87,267 million, up ¥6,560 million, or 8.1%, year on year. In terms of profit, although the cost-of-sales ratio rose, gross profit increased by ¥1,259 million year on year on higher sales. Meanwhile, selling, general and administrative expenses increased by ¥1,496 million, while research and development expenses declined by ¥1,446 million. As a result, operating profit was ¥4,465 million, down ¥237 million, or 5.0%, year on year.」
For the nine months ended the third quarter, net sales increased 8.1% year on year, while operating profit declined 5.0% and net income attributable to owners of the parent declined 10.6%. - FY2024-Q2Higher sales, higher operating profit, higher net incomeAnnual report
「Net sales increased to ¥54,937 million, up ¥5,844 million, or 11.9%, year on year. In terms of profit, although the cost-of-sales ratio rose, gross profit increased by ¥2,033 million year on year on higher sales. Meanwhile, selling, general and administrative expenses increased by ¥1,666 million, while research and development expenses declined by ¥656 million. As a result, operating profit increased to ¥1,144 million, up ¥366 million, or 47.2%, year on year.」
For the six months ended the second quarter, net sales increased 11.9%, operating profit increased 47.2%, and net income attributable to owners of the parent increased 41.4% year on year. - FY2024-Q1Higher net sales, higher operating income, lower net incomeAnnual report
「Net sales ¥27,854 million (up 13.1% year on year) Operating profit ¥710 million (up 45.1% year on year) Net income attributable to owners of the parent ¥676 million (down 42.8% year on year)」
In the first quarter of the fiscal year ending March 2024, sales and operating profit increased, while net income attributable to owners of the parent declined due in part to the absence of the insurance gain related to the fire at the West Japan Distribution Center in the same period of the previous year. - FY2023Higher sales and operating profitAnnual report
「Total sales increased to ¥113,270 million, an increase of ¥7,735 million, or 7.3%, from the previous fiscal year, achieving the consolidated earnings forecast. Operating profit increased to ¥5,123 million, up ¥115 million, or 2.3%, from the previous fiscal year.」
For the fiscal year ended March 2023, net sales were ¥113,270 million, up 7.3% year on year, and operating profit was ¥5,123 million, up 2.3%, achieving the consolidated earnings forecast. - FY2023-Q3Higher sales and operating profitAnnual report
「Results for the nine months ended the third quarter of the current consolidated fiscal year: Net sales ¥80,707 million (up 3.8% year on year); Operating profit ¥4,702 million (up 60.7% year on year)」
For the nine months ended the third quarter, net sales increased 3.8% year on year and operating profit rose 60.7%, resulting in higher sales and profit. - FY2023-Q2Flat sales, return to operating profitabilityAnnual report
「Results for the six months ended the second quarter of the current consolidated fiscal year: Net sales ¥49,093 million (down 0.0% year on year); Operating profit ¥777 million (operating loss of ¥68 million in the same period of the previous year)」
For the six months ended the second quarter, net sales were essentially flat, down 0.0% year on year, while operating profit turned positive at ¥777 million, compared with an operating loss in the same period of the previous year. - FY2023-Q1Decline in revenue; increase in operating profitAnnual report
「Although sales of the new-drug portfolio grew, total sales of new drugs and other products in Japan remained below the same period of the previous year, due in part to the impact of the drug price revision (in the 8% range for Kyorin Pharmaceutical Co., Ltd.). Meanwhile, sales of generic drugs increased, bringing total sales to ¥24,619 million, down 0.3% year on year.」
While sales of some new drugs and generic drugs grew, overall sales declined 0.3% year on year due to the drug price revision and other factors. Operating profit improved to ¥489 million from an operating loss in the same period of the previous year, owing to lower selling, general and administrative expenses. - FY2022-Q3Higher Revenue and Lower Operating ProfitAnnual report
「Results for the nine months ended the third quarter: revenue of ¥77.717 billion, compared with ¥74.955 billion in the same period of the previous year; operating profit of ¥2.926 billion, compared with ¥4.114 billion in the same period of the previous year」
For the nine months ended the third quarter, revenue exceeded the same period of the previous year, while operating profit was lower due to the higher cost-of-sales ratio. - FY2022-Q2Higher revenue and an operating lossAnnual report
「Revenue was ¥49.102 billion, compared with ¥47.735 billion in the same period of the previous year, and remained above forecast. As a result, the operating loss was ¥68 million, compared with operating profit of ¥1.502 billion in the same period of the previous year.」
Although revenue exceeded the same period of the previous year and forecasts, the company swung to an operating loss due in part to the impact of a higher cost-of-sales ratio. - FY2022-Q1WorsenedAnnual report
「As a result, the operating loss was ¥756 million, compared with operating profit of ¥2.014 billion in the same period of the previous year, and the net loss attributable to owners of the parent was ¥462 million, compared with net income attributable to owners of the parent of ¥1.609 billion in the same period of the previous year.」
Although revenue was broadly unchanged from the same period of the previous year, operating profit and net income turned to losses due to the recognition of upfront contract payments and a higher cost-of-sales ratio, among other factors. - FY2021-Q3WorsenedAnnual report
「Due to drug price revisions and restrictions on medical consultations associated with the spread of COVID-19, the prescription drug market in our group’s key areas remained in negative growth, and sales of new drugs and other products in Japan fell below the previous year due in part to curtailed MR activities. Although sales of generic drugs increased, overall revenue was ¥74.955 billion, a decrease of ¥3.658 billion, or 4.7%, year on year.」
Although sales of generic drugs increased, overall revenue decreased 4.7% year on year due to lower sales of new drugs and other products in Japan. Operating profit also decreased 21.9%, resulting in a further decline in revenue and earnings. - FY2021-Q2Decline in revenue; increase in operating profitAnnual report
「Although revenue decreased, gross profit increased by ¥273 million from the same period of the previous year due to an improved cost-of-sales ratio. Selling, general and administrative expenses decreased by ¥445 million, including a ¥9 million increase in R&D expenses, due to cost-cutting efforts and the curtailment of MR activities at medical institutions associated with the spread of COVID-19. Operating profit was ¥1.502 billion, an increase of ¥718 million, or 91.7%, year on year.」
For the six months ended the second quarter, revenue decreased 1.2% year on year, while operating profit increased 91.7% due to the improved cost-of-sales ratio and lower selling, general and administrative expenses. - FY2021-Q1Decline in revenue; increase in operating profitAnnual report
「Revenue from new drugs and other products in Japan fell below the previous year as the market remained weak due to drug price revisions and the spread of COVID-19. Although sales of generic drugs increased, overall revenue was ¥24.689 billion, a decrease of ¥1.060 billion, or 4.1%, year on year. Gross profit decreased by ¥232 million from the same period of the previous year due to lower revenue, but selling, general and administrative expenses, including R&D expenses, decreased by ¥671 million due to cost-cutting efforts and the curtailment of MR activities at medical institutions associated with the spread of COVID-19. Operating profit was ¥2.014 billion, an increase of ¥438 million, or 27.8%, year on year.」
In the first quarter, revenue decreased 4.1% year on year, while operating profit increased 27.8% due to lower selling, general and administrative expenses. - FY2020WorsenedAnnual report
「Overall revenue was ¥109.983 billion, a decrease of ¥3.637 billion, or 3.2%, from the previous fiscal year. Operating profit was ¥7.503 billion, a decrease of ¥1.469 billion, or 16.4%, from the previous fiscal year.」
For the full year, revenue decreased 3.2% and operating profit decreased 16.4% from the previous fiscal year, turning from growth in both revenue and earnings the previous year to declines in both. - FY2020-Q3WorsenedAnnual report
「Overall revenue was ¥78.614 billion, a decrease of ¥3.402 billion, or 4.1%, year on year. Operating profit was ¥5.271 billion, a decrease of ¥1.522 billion, or 22.4%, year on year.」
For the nine months ended the third quarter, revenue decreased 4.1% year on year and operating profit decreased 22.4%, resulting in a further decline in revenue and earnings. - FY2020-Q2WorsenedAnnual report
「Overall revenue was ¥48.299 billion, a decrease of ¥2.061 billion, or 4.1%, year on year. Operating profit was ¥783 million, a decrease of ¥2.069 billion, or 72.5%, year on year.」
For the six months ended the second quarter, revenue decreased 4.1% year on year and operating profit decreased 72.5%, resulting in a further decline in revenue and earnings. - FY2020-Q1MitigatedAnnual report
「Overall revenue was ¥25.749 billion, an increase of ¥618 million, or 2.5%, year on year. Operating profit was ¥1.575 billion, an increase of ¥255 million, or 19.3%, year on year.」
In the first quarter, revenue increased 2.5% year on year and operating profit increased 19.3%, improving results from the previous year’s decline in revenue and earnings. - FY2019MitigatedAnnual report
「Overall revenue was ¥113.620 billion, an increase of ¥2.979 billion, or 2.7%, from the previous fiscal year. Operating profit was ¥8.972 billion, an increase of ¥150 million, or 1.7%, from the previous fiscal year.」
Both revenue and operating profit increased from the previous fiscal year, improving results from the prior year’s decline in revenue and earnings. - FY2019-Q3WorsenedAnnual report
「Overall revenue was ¥82.017 billion, a decrease of ¥906 million, or 1.1%, year on year. Operating profit was ¥6.794 billion, a decrease of ¥1.011 billion, or 13.0%, year on year.」
For the nine months ended the third quarter, revenue decreased 1.1% year on year and operating profit decreased 13.0%, continuing the decline in revenue and earnings. - FY2019-Q2MitigatedAnnual report
「Overall revenue was ¥50.360 billion, a decrease of ¥398 million, or 0.8%, year on year. Gross profit decreased by ¥1.027 billion from the same period of the previous year due in part to a higher cost-of-sales ratio following the drug price revision. On the other hand, selling, general and administrative expenses decreased by ¥2.437 billion, including a ¥2.148 billion decrease in R&D expenses, as a result of cost-cutting efforts, and operating profit was ¥2.852 billion, an increase of ¥1.409 billion, or 97.6%, year on year.」
Although revenue decreased 0.8% year on year due to the drug price revision and other factors, operating profit increased 97.6% due to cost reductions, indicating an improvement in profitability amid the ongoing trend of declining revenue and earnings. - FY2019-Q1WorsenedAnnual report
「Revenue: ¥25.131 billion (down 5.0% year on year); operating profit: ¥1.320 billion (down 49.1% year on year)」
In the first quarter, revenue decreased 5.0% year on year and operating profit decreased 49.1%, resulting in a further decline in revenue and earnings. - FY2018WorsenedAnnual report
「Overall revenue was ¥110.640 billion, a decrease of ¥4.732 billion, or 4.1%, from the previous fiscal year. Operating profit was ¥8.822 billion, a decrease of ¥1.590 billion, or 15.3%, from the previous fiscal year.」
For the full year, revenue and earnings declined, with revenue down 4.1% and operating profit down 15.3%. - FY2018-Q3MitigatedAnnual report
「Selling, general and administrative expenses decreased by ¥2.557 billion from the same period of the previous year, including a ¥802 million decrease in R&D expenses, as a result of cost-cutting efforts. Operating profit was ¥7.805 billion, an increase of ¥492 million, or 6.7%, year on year.」
Although revenue was below the year-earlier level, operating profit increased 6.7% year on year due to cost reductions and upfront payments received from overseas, indicating an improvement in profitability from the previous trend of declining revenue and earnings. - FY2018-Q2RestatedAnnual report
「Overall revenue was ¥50.758 billion, a decrease of ¥3.869 billion, or 7.1%, year on year. Operating profit was ¥1.443 billion, a decrease of ¥2.219 billion, or 60.6%, year on year.」
Revenue and earnings declined in the six months ended the second quarter, mainly due to lower sales of new drugs following the expiration of patents on key products. - FY2018-Q1RestatedAnnual report
「Total revenue was ¥26.458 billion, a decrease of ¥1.249 billion, or 4.5%, year on year. Operating profit was ¥2.595 billion, a decrease of ¥648 million, or 20.0%, year on year.」
In the first quarter, revenue decreased 4.5% year on year and operating profit decreased 20.0%. The main factor behind the revenue decline was lower sales following the expiration of patents on key products. - FY2017First statedAnnual report
「Revenue was ¥115.373 billion, a decrease of ¥410.9 million, or 3.4%, year on year. Operating profit was ¥10.413 billion, a decrease of ¥9.222 billion, or 47.0%, year on year.」
For the year, revenue decreased 3.4% year on year and operating profit decreased 47.0%.